Spero Therapeutics Inc (SPRO) Stock AnalysisSPROSpero Therapeutics Inc

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Spero Therapeutics Inc is a good buy right now at a current price of $1.04, especially considering the analyst price target of $6, which suggests a potential upside of over 480%. The company has a strong gross margin of 100% and a favorable forward P/E ratio of 0, indicating no earnings pressure from valuations. However, the main risk is the significant net loss of $9.6 million reported in Q2 2026, which highlights ongoing financial challenges.

4 analysts cover SPRO: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 4.00.